Skip to main content

Advertisement

Log in

Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Although circulating microRNAs (miRNAs) were frequently detected in sera of cancer patients, there is still a lack of analysis of the dynamic changes of miRNAs expression in sera of pre- and post-operative lung carcinoma patients. Thus, we conducted quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to examine the expression of four miRNAs (miR-21, miR-205, miR-30d, and miR-24) in the sera of a set of 82 pre-operative lung carcinoma patients and paired 10 days post-operative patients, as well as in 50 normal volunteers. We showed that, compared to that in normal volunteers, the expression of miR-21, miR-205, miR-30d, and miR-24 was increased in lung cancer sera samples, as well as in sera of early stage lung cancer patients according to their clinical-pathological characteristics. The area under roc curves (AUCs) for levels of miR-21, miR-205, miR-30d, and miR-24 in sera were significantly higher than those for Carcinoma embryonic antigen (CEA) (P < 0.05), whereas the AUC for combination of serum levels of miRNA with serum CEA showed no significant difference from that for serum levels of miRNAs only (P > 0.05). The expression levels of miR-21 and miR-24 were significantly decreased in post-operative sera compared with levels in paired pre-operative sera (P = 0.0004 and <0.0001, respectively). In addition, high expressions of miR-21 and miR-30d in pre-operative sera were independently correlated with shorter overall survival in lung cancer patients (log-rank test: P = 0.0498, 0.0019). In summary, our results suggest that miR-21, miR-205, miR-30d, and miR-24 may serve as potential novel non-invasive biomarkers for diagnosis of lung cancer. In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Yang L, et al. Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer. 2004;90:2157–66.

    PubMed  CAS  Google Scholar 

  3. Verdecchia A, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–96.

    Article  PubMed  Google Scholar 

  4. Boeri M, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108:3713–8.

    Article  PubMed  CAS  Google Scholar 

  5. Chen X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.

    Article  PubMed  CAS  Google Scholar 

  6. Hu Z, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–6.

    Article  PubMed  Google Scholar 

  7. Chen X, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for non-small cell lung cancer diagnosis. In J Cancer. 2012;130:1620–8.

    CAS  Google Scholar 

  8. Keller A, et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 2011;8:506–16.

    Article  PubMed  CAS  Google Scholar 

  9. Liu XG, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29:618–26.

    Article  PubMed  CAS  Google Scholar 

  10. Lebanony D, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non–small-cell lung carcinoma. J Clin Oncol. 2009;27:2030–7.

    Article  PubMed  CAS  Google Scholar 

  11. Xie L, et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer. 2010;10:591–6.

    Article  PubMed  Google Scholar 

  12. Huang Z, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. In J Cancer. 2010;127:118–26.

    CAS  Google Scholar 

  13. Wang J, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res. 2009;2:807–13.

    Article  CAS  Google Scholar 

  14. Heneghan HM, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.

    Article  PubMed  Google Scholar 

  15. Zheng H, et al. Define relative incomplete resection by highest mediastinal lymph node metastasis for non-small cell lung cancers: rationale based on prognosis analysis. Lung Cancer. 2011;72:348–54.

    Article  PubMed  Google Scholar 

  16. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.

    Article  PubMed  CAS  Google Scholar 

  17. Zheng D, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4:575–86.

    PubMed  CAS  Google Scholar 

  18. Frezzetti D, et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene. 2010;30:275–86.

    Article  PubMed  Google Scholar 

  19. Ma X, et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA. 2011;108:10144–9.

    Article  PubMed  CAS  Google Scholar 

  20. Hatley ME, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18:282–93.

    Article  PubMed  CAS  Google Scholar 

  21. Seike M, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA. 2009;106:12085–90.

    Article  PubMed  CAS  Google Scholar 

  22. Zhou X, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010;90:144–55.

    Article  PubMed  CAS  Google Scholar 

  23. Kumar M, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 2010;30:843–53.

    Article  PubMed  Google Scholar 

  24. Yao J, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010;51:846–56.

    PubMed  CAS  Google Scholar 

  25. Qin W, et al. MiR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One. 2010;5:e9429.

    Article  PubMed  Google Scholar 

  26. Majid S, et al. MicroRNA-205 directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer. 2010;116:5637–49.

    Article  PubMed  CAS  Google Scholar 

  27. Cheng H, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6:e17745.

    Article  PubMed  CAS  Google Scholar 

  28. Duttagupta R, et al. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6:e20769.

    Article  PubMed  CAS  Google Scholar 

  29. Lodes MJ, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4:e6229.

    Article  PubMed  Google Scholar 

  30. Del Vescovo V, et al. miR-205 Expression levels in non-small cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. 2011;35:268–75.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the Science and Technology Program of Zhoushan (No.091042, No. 2011C12039) and the Grants from Medical Bureau of Zhejiang Province (No. 2009A210).

Conflict of interest

The authors declare no conflict of interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong-Kui Zhang.

Additional information

Han-Bo Le, Wang-Yu Zhu, and Dong-Dong Chen are equally contributed to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le, HB., Zhu, WY., Chen, DD. et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol 29, 3190–3197 (2012). https://doi.org/10.1007/s12032-012-0303-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0303-z

Keywords

Navigation